Health Catalyst vs AbbVie
Side-by-side comparison of AI visibility scores, market position, and capabilities
$307M revenue 2024 (up from $296M 2023); $316M TTM Jun 2025; $26M adjusted EBITDA; 100M+ patient records; expects double-digit growth 2025; low-20s net new platform clients 2024; healthcare analytics leader
About
Health Catalyst is a healthcare data and analytics company founded in 2008 in Salt Lake City, Utah, built on the mission of being a catalyst for massive, measurable, data-informed improvement in the health of humanity. The company's core technology — the Health Catalyst Data Operating System (DOS) — provides healthcare organizations with a cloud-based data platform that aggregates clinical, financial, and operational data from disparate source systems into a unified analytics environment designed specifically for the complexity of healthcare data.\n\nHealth Catalyst serves 40+ health systems and hundreds of hospitals, offering analytics applications, embedded data science teams, and technology-enabled services that help organizations improve quality outcomes, reduce costs, and optimize operations. Its suite includes applications for perioperative efficiency, population health management, sepsis surveillance, and financial analytics. The company differentiates through a unique Tech-Enabled Managed Services model, embedding data scientists alongside health system teams to ensure analytics drive measurable operational change rather than sitting unused.\n\nHealth Catalyst generated $307M in revenue in 2024, up from $296M in 2023, with $26M in adjusted EBITDA and a database of over 100 million patient records. As a publicly traded company (HCAT), it has built one of the largest healthcare-specific analytics platforms in the US. With regulatory pressure, value-based care contracts, and margin compression intensifying across health systems, Health Catalyst's integrated data platform and domain expertise position it as a strategic partner for health systems pursuing data-driven operational transformation.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
About
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.